Clinical Trial Update: Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating the 52-week efficacy and safety of bimagrumab (BYM338) in Sporadic Inclusion Body Myositis, assessing physical function, muscl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sporadic Inclusion Body Myositis

Drugs mentioned

• Bimagrumab (bimagrumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sporadic Inclusion Body Myositis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-05-12